Data Published In Nature Biotechnology Show Messenger (m)RNA Prophylactic Vaccines Based On CureVac's RNActive® Technology Demonstrate Immunogenicity And Protection Against Influenza Virus Infection

Additional data revealed that full protection was achieved upon single-dose immunization against influenza A/PR8 with a multi-component HA and NA mRNA vaccine. Furthermore, mRNA vaccines provided heterologous protection; vaccination with PR8 nucleoprotein (NP) mRNA led to protection against homologous PR8 (H1N1) or heterologous MB1 (H5N1) virus. Moreover, mRNA vaccines provided immunogenicity in ferrets, the animal model of choice for preclinical proof-of-concept studies in influenza research, and pigs compared to a licensed trivalent vaccine of corresponding specificity.

The publication, entitled 'Protective efficacy of in vitro synthesized, specific messenger RNA vaccines against influenza A virus infection,' was published online in Nature Biotechnology on Nov. 25.

About RNActive CureVac is combining both the antigenic and adjuvant properties of mRNAs to develop novel and effective mRNA vaccines. RNActive vaccines are comprised of modified and formulated mRNA with three distinct features: The mRNA vaccines are translated into the target antigens, and the formulation and modifications lead to translatability ensuring (1) strong antigen expression, (2) increased stability and (3) enhanced immune-stimulatory activity.



About CureVacCureVac is developing an entirely new class of therapies based on a fundamental new understanding of the medical potential of mRNA. Using its RNA technology platform, CureVac is currently developing novel therapeutic mRNA vaccines (RNActive) for cancer and prophylactic vaccines for infectious diseases and adjuvants based on long, non-coding RNAs (RNAdjuvant ^®) for enhancing the immune response of other vaccines. The company has successfully completed Phase 1/2a studies with its RNActive cancer vaccines in prostate cancer and non-small cell lung cancer (NSCLC). Results so far have shown that mRNA-based products are safe and capable of inducing balanced immune responses including humoral and cellular, Th1 and Th2 and effector and memory responses. In addition to developing its own pipeline, CureVac is collaborating with Sanofi Pasteur and In-Cell-Art on a $33.1 million project co-funded by Defense Advanced Research Projects Agency (DARPA) for the development of prophylactic vaccines in infectious diseases utilizing its RNActive technology platform. For more information, please visit: http://www.curevac.com.

Media Contacts                                                                       Martina Schwarzkopf, Ph.D.   Tony Russo, Ph.D.                                         Russo Partners                                                                      T: + 1 [phone]M: + 1 [phone]                                     T: + 1 [phone] [e-mail]    [e-mail]    

Marina Bulach, Executive AssistantCureVac GmbHT: + 49 (7071) 920 53 20 [e-mail]  

 

« First ‹ Previous 1 2 3 Next › Last »